Molecular pharmaceutics

Targeted delivery of AR-V7 blocking RNA using dual PSMA aptamers reduces growth of prostate cancer resistant to enzalutamide

Updated

Abstract

A serum-stable bivalent prostate-specific membrane antigen aptamer-AR-V7 siRNA chimera (PAP) can effectively knock down both full-length androgen receptors and AR-V7 in prostate cancer cells.

  • AR-V7 is associated with resistance to FDA-approved second-generation androgen receptor antagonists enzalutamide and abiraterone.
  • Current androgen receptor antagonists cannot target AR-V7 due to its structural characteristics.
  • Targeting the androgen receptor N-terminal domain is crucial to overcoming enzalutamide resistance.
  • PAP has been shown to resensitize prostate cancer cell lines to enzalutamide treatment.
  • In mouse models, the combination of enzalutamide and PAP significantly inhibits the growth of prostate cancer xenografts.
  • PAP demonstrates low toxicity, suggesting its potential as a new antiandrogen treatment for enzalutamide-resistant prostate cancer.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free